Income Tax Raid Uncovers ₹300 Crore Tax Evasion in Bengaluru Pharma Group

Alright, let’s chat about something that really matters to all of us: trust in medicine. It’s something we don’t think about much until it’s shaken, and recently, it got a pretty big jolt.

Picture this: it’s July 2022, and in Bengaluru, tax officials are making waves with one of the biggest raids anyone’s seen in a while. They’re targeting a major pharmaceutical company—most people think it’s Micro Labs Ltd., the company behind Dolo-650. If you’ve had a fever in the last few years, you’ve probably heard of Dolo-650. It became a household name during the pandemic, not just in India but in over 50 countries.

But here’s the twist: this raid wasn’t just about checking numbers. Officials hit up 36 spots across nine states, including the company’s main places and even the homes of top bosses like CMD Dileep Surana and Director Anand Surana. That’s a lot of ground to cover, and it tells you something big was up.

So, what did they find? Well, it turns out the company had been handing out gifts—really big gifts—worth a jaw-dropping Rs 1,000 crore to doctors. And I’m not talking about pens or notepads here. We’re talking luxury travel for doctors and their families, fancy gifts, even international trips all dressed up as medical conferences. All this was carefully written down in the books under names like “Sales and Promotion,” “Seminars and Symposiums,” and “Medical Advisories.”

Why does this matter to you and me? Because when doctors get perks for prescribing certain medicines, it can mess with their decisions. The Supreme Court has said loud and clear: giving doctors gold coins, gadgets, or vacations is not okay. It’s considered prescription manipulation. And guess who ends up paying for all that? Us. The cost of these gifts gets added to the price of medicines, making healthcare more expensive for everyone.

But wait, there’s more. The tax folks also found some pretty clever tricks in the company’s books. They’re accused of skipping out on more than Rs 300 crore in taxes by inflating deductions, hiding real expenses, and making big claims for research and development. There were even issues with tax deduction at source (TDS) rules, especially with third-party bulk drug manufacturers. When companies play games with their books, it’s regular people who end up paying the price.

The law is pretty clear on this. In February 2022, the Supreme Court ruled that pharmaceutical companies can’t claim tax deductions for gifts to doctors. The court called these practices “prohibited by law,” and said the cost of these freebies usually ends up in the price of medicines. So, marketing expenses like these can’t be claimed as business deductions under Section 37(1) of the Income Tax Act.

To tackle all this, the Department of Pharmaceuticals introduced the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) 2024, which started last March. This new code is all about transparency and accountability. It sets clear rules for marketing, limits how many samples can be given out, and sets up Ethics Committees for Pharma Marketing Practices (ECPMP) to handle complaints. Industry groups are now supposed to keep an eye on things and make sure everyone plays by the rules.

During the raids, officials also found unaccounted cash—Rs 1.20 crore—and gold and diamond jewelry worth Rs 1.40 crore. That’s a lot of hidden value, and it adds even more weight to the case. The investigation is still going on, so there might be more to come.

This isn’t just a one-off thing, either. Over the past few years, the Income Tax Department has been cracking down on the pharmaceutical sector. In February 2021, a Hyderabad-based group was found to have unaccounted income of about Rs 400 crore. In June 2022, another group in Delhi-NCR and Haryana got caught up in unaccounted cash sales and hawala transactions worth around Rs 25 crore. And in July 2022, healthcare providers in Haryana and Delhi-NCR were investigated for keeping parallel books and under-reporting cash receipts. It’s a pattern that shows the authorities are serious about cleaning things up.

So, what’s the takeaway for the rest of us? It’s a reminder that when doctors are influenced by gifts, patient care can take a backseat. Healthcare costs go up as companies pass the cost of freebies onto patients. Tax compliance becomes a bigger issue, and corporate governance is under the microscope.

At the end of the day, this raid on a Bengaluru pharmaceutical giant is more than just a headline. It’s a wake-up call for the whole industry. The scale of the freebies—Rs 1,000 crore—and the clever tax tricks uncovered show just how much work is left to be done. As the investigation continues, this case could be the push the industry needs to become more transparent and patient-focused.